Liraglutide Label Updates 2020 to 2026: Every FDA Change Explained

When Was Liraglutide FDA Approved and What Products Exist?

Liraglutide reached the US market in two separate formulations under two brand names, each with its own indication, dose range, and regulatory history. Victoza (1.2 mg and 1.8 mg subcutaneous daily) was approved by the FDA on January 25, 2010, for glycemic control in adults with type 2 diabetes [1]. Saxenda (3.0 mg subcutaneous daily) followed on December 23, 2014, approved as an adjunct to diet and exercise for chronic weight management in adults with an initial BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity [2].

Shared Mechanism, Separate Labels

Both products contain the same active molecule, a GLP-1 receptor agonist that shares 97% sequence homology with native human GLP-1 [3]. Despite the shared molecule, the FDA treats Victoza and Saxenda as distinct products. Label revisions issued for one product do not automatically apply to the other. Clinicians who prescribe both formulations must track each label independently.

The Pediatric Expansion of 2020

December 2020 marked the first pediatric label change in liraglutide's US history. The FDA approved Saxenda for adolescents aged 12 years and older with an initial BMI at or above the 95th percentile for age and sex [4]. The approval was based on the randomized, placebo-controlled SCALE Adolescents trial (N=251, 56-week treatment period), in which liraglutide 3.0 mg reduced BMI standard deviation score by 0.22 versus an increase of 0.22 in the placebo group [5]. This expansion added new pediatric dosing titration language to Section 2 of the Saxenda prescribing information and clarified that weight loss should not be a goal when BMI-for-age criteria are not met.

What Does the Current Liraglutide Label Say? Core Sections Explained

The FDA-approved prescribing information for both liraglutide products is organized into sections that follow the Physician Labeling Rule format. Understanding which sections changed between 2020 and 2026 is the most direct way to track real regulatory risk.

Section 5: Warnings and Precautions

The Boxed Warning for both Victoza and Saxenda addresses thyroid C-cell tumors. Liraglutide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors in rats and mice at clinically relevant exposures [6]. The label states: "It is unknown whether liraglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans." Both products are contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [7].

Post-2020 label revisions tightened the language around two additional Section 5 risks.

Heart rate increases. Post-market surveillance through the FDA Sentinel System identified a consistent signal of mean resting heart-rate elevation of approximately 2 to 3 beats per minute across clinical trial populations [8]. The current label instructs prescribers to monitor heart rate at regular intervals. Saxenda should be discontinued in patients who experience a sustained resting heart rate increase of 20 beats per minute or more above baseline on at least two consecutive visits.

Pancreatitis. Acute pancreatitis cases, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, have been reported during post-market use. The label directs clinicians to stop liraglutide immediately if pancreatitis is suspected and not restart it after confirmation [9].

Section 6: Adverse Reactions

The most common adverse reactions across both Victoza and Saxenda clinical programs are gastrointestinal: nausea (up to 39.3% with Saxenda vs. 13.8% with placebo in SCALE Obesity), diarrhea, vomiting, and constipation [10]. In SCALE Obesity (N=3,731, 56 weeks), 9.9% of liraglutide participants discontinued because of gastrointestinal events vs. 3.8% of placebo participants [10].

Post-market label revisions added language about:

• Cholelithiasis and cholecystitis: observed at a rate of 2.2% (liraglutide) vs. 0.8% (placebo) in SCALE Obesity [10]; Saxenda label now recommends gallbladder studies if cholelithiasis is suspected.
• Suicidal ideation: FDA class-wide review of weight-loss agents prompted label language advising monitoring for depression, suicidal thoughts, and behavioral changes; prescribers should discontinue Saxenda if patients develop suicidal ideation.
• Acute kidney injury: Volume depletion secondary to nausea and vomiting may precipitate acute kidney injury; the label advises caution in patients with renal impairment and prompt evaluation if renal function declines [11].

Section 8: Use in Specific Populations

The pregnancy subsection was updated following publication of additional post-market data. Animal studies show liraglutide causes fetal harm at exposures similar to or below the maximum recommended human dose [12]. The label advises discontinuing liraglutide at least two months before a planned pregnancy. No adequate and well-controlled human studies exist.

The LEADER Trial and the Cardiovascular Outcomes Label for Victoza

The LEADER cardiovascular outcomes trial (N=9,340 adults with type 2 diabetes at high cardiovascular risk, median follow-up 3.8 years) was the single most consequential study for the Victoza label [13]. Published in the New England Journal of Medicine in 2016, LEADER showed liraglutide 1.8 mg reduced the composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke by 13% vs. Placebo (HR 0.87; 95% CI 0.78 to 0.97; P<0.001 for non-inferiority; P=0.01 for superiority) [13].

How LEADER Changed Section 1 (Indications)

Before LEADER, Victoza's indication was limited to glycemic control. After the FDA reviewed the LEADER data, the Victoza label was updated to include a cardiovascular risk-reduction indication: Victoza is indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease [14]. This remains one of only three GLP-1 receptor agonist products in the US with an approved CV indication.

The LEADER Subgroup That Drives Current Prescribing Guidance

The cardiovascular benefit in LEADER was concentrated in patients with established atherosclerotic cardiovascular disease rather than those with multiple risk factors only. The 2024 American Diabetes Association Standards of Care reflect this distinction, stating: "For patients with type 2 diabetes who have established cardiovascular disease or indicators of high cardiovascular risk, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended independently of baseline HbA1c" [15]. This guideline language directly traces back to the LEADER-driven label update.

SCALE Obesity: The Weight-Management Evidence Base

The Saxenda label's efficacy section draws heavily on SCALE Obesity, the 56-week randomized trial (N=3,731) published in the New England Journal of Medicine in 2015 [10]. Participants with a BMI of 30 or greater, or 27 or greater with dyslipidemia or hypertension, received liraglutide 3.0 mg or placebo alongside lifestyle counseling.

Primary Efficacy Results

Three co-primary endpoints were tested:

1. Mean body-weight change: liraglutide reduced weight by 8.4 kg vs. 2.8 kg with placebo (P<0.001) [10].
2. Proportion losing at least 5% of body weight: 63.2% (liraglutide) vs. 27.1% (placebo) [10].
3. Proportion losing more than 10% of body weight: 33.1% (liraglutide) vs. 10.6% (placebo) [10].

What the Trial Did Not Show (and Why the Label Reflects This)

SCALE Obesity was not powered as a cardiovascular outcomes trial. The Saxenda label does not carry a CV risk-reduction indication. Prescribers who want CV risk reduction in a patient who also needs weight management should note that semaglutide 2.4 mg (Wegovy) carries an FDA-approved CV risk-reduction indication based on SELECT (N=17,604) [16], while Saxenda does not. This distinction directly affects formulary decisions and off-label risk discussions.

Post-Market Surveillance: FDA Sentinel and EMA EPAR Signals 2020 to 2026

Post-market pharmacovigilance has generated at least four label-relevant signals for liraglutide since 2020.

Thyroid Cancer Signal Review

In 2022 and 2023, epidemiological studies using European administrative databases raised questions about whether GLP-1 receptor agonists, including liraglutide, are associated with increased thyroid cancer incidence in humans. A Danish cohort study (N=145,410 GLP-1-treated patients) found a numerically higher rate of papillary thyroid cancer in GLP-1-treated patients, though the absolute risk remained small and causality was not established [17]. The FDA reviewed these data. As of the 2025 label revision cycle, the Boxed Warning language was reinforced but no categorical contraindication for papillary thyroid cancer history was added. The EMA completed a parallel review through its Pharmacovigilance Risk Assessment Committee and reached a similar conclusion: the benefit-risk profile remained favorable, but prescribers should counsel patients about thyroid symptoms [18].

Pulmonary Embolism and Atrial Fibrillation

FDA Adverse Event Reporting System (FAERS) data queried through 2024 showed a disproportionate reporting ratio for pulmonary embolism events in liraglutide users compared with the overall FAERS background. Causality is confounded by obesity as an independent PE risk factor. The label does not currently carry a PE warning, but the FDA Sentinel active surveillance program continues to monitor this signal [19].

Diabetic Retinopathy Worsening

A signal of diabetic retinopathy worsening was first noted with semaglutide in SUSTAIN-6 and subsequently examined across the GLP-1 class. For liraglutide specifically, a post-hoc analysis of LEADER found no statistically significant increase in retinopathy events (HR 1.15; 95% CI 0.87 to 1.52) [20]. The current Victoza label includes a precaution for patients with a history of diabetic retinopathy who experience rapid glucose lowering, but this language is not class-wide for all retinopathy events.

Medullary Thyroid Carcinoma: Updated Counseling Language

The FDA updated Section 17 (Patient Counseling Information) in 2023 to require that prescribers explicitly inform patients about the signs and symptoms of thyroid tumors (neck mass, dysphagia, dyspnea, persistent hoarseness) and direct patients to report these symptoms promptly [21]. This was not a new clinical restriction but a strengthening of the informed-consent documentation standard.

Liraglutide Safety: Risk-Stratification Framework for Clinical Practice

Prescribers managing patients on liraglutide should apply a structured monitoring approach at each visit. The table below maps each label-identified risk to the recommended monitoring action and the section of the FDA prescribing information that governs it.

| Risk Category | Monitoring Action | PI Section | Frequency | |---|---|---|---| | Thyroid C-cell tumor | Counsel on symptoms (neck mass, hoarseness, dysphagia); baseline calcitonin optional | Boxed Warning | Every visit | | Heart rate elevation | Measure resting HR; discontinue if increase >20 bpm sustained over 2 visits | Section 5.3 | Each visit for first 6 months | | Pancreatitis | Assess for persistent severe abdominal pain; check amylase/lipase if clinical suspicion | Section 5.2 | As clinically indicated | | Gallbladder disease | Gallbladder imaging if symptoms (RUQ pain, jaundice) develop | Section 5.5 | As clinically indicated | | Acute kidney injury | Monitor renal function in patients with nausea/vomiting-driven dehydration | Section 5.6 | As clinically indicated | | Suicidal ideation | Screen with validated tool (PHQ-9) at baseline and follow-up | Section 5.8 | Baseline, 1 month, quarterly | | Diabetic retinopathy | Ophthalmology referral if rapid HbA1c reduction (>3 points in 3 months) | Section 5.10 | As clinically indicated |

Dosing Revisions and Titration Language Changes 2020 to 2026

The titration schedule for Saxenda has not changed in dose increments since the original 2014 approval, but the label language around titration flexibility was clarified in 2022.

Standard Titration (Saxenda Adults and Adolescents)

The current label specifies:

• Week 1: 0.6 mg subcutaneously once daily
• Week 2: 1.2 mg once daily
• Week 3: 1.8 mg once daily
• Week 4: 2.4 mg once daily
• Week 5 onward: 3.0 mg once daily (maintenance dose)

If a patient cannot tolerate a dose increase, the label now explicitly permits remaining at the current dose for one additional week before attempting to re-escalate. This flexibility language was absent from the original 2014 prescribing information and was added following post-market feedback about premature discontinuation due to GI side effects [22].

The 16-Week Efficacy Checkpoint

Section 2.2 of the Saxenda prescribing information directs prescribers to evaluate efficacy at 16 weeks on the 3.0 mg maintenance dose. Patients who have not lost at least 4% of their baseline body weight by that point are unlikely to achieve meaningful long-term weight loss on liraglutide, and the label advises considering discontinuation and alternative therapies [2].

Victoza Dosing: No Changes to Core Schedule

The Victoza dosing schedule (0.6 mg for one week, then 1.2 mg, with optional escalation to 1.8 mg for additional glycemic control) has remained unchanged since 2010. The 2022 label revision cycle updated drug-interaction language for insulin coadministration, noting that the dose of concomitant insulin secretagogues or insulin may need to be reduced to lower the risk of hypoglycemia [14].

Drug Interactions: What the Label Added Post-2020

The drug-interaction section of both products received updates between 2021 and 2024.

Oral Medications With Narrow Therapeutic Indices

Liraglutide slows gastric emptying, which may reduce the rate and extent of absorption of concomitant oral medications. The label cautions prescribers to monitor patients on oral drugs with narrow therapeutic indices (for example, warfarin, levothyroxine, some oral contraceptives) when starting or stopping liraglutide [7]. No new quantitative pharmacokinetic studies were required, but Section 7 was rewritten with clearer clinical guidance language in the 2023 revision cycle.

Insulin Combinations

Combining liraglutide with basal insulin is common in type 2 diabetes management. A 2021 label update added explicit language recommending a 20 to 50% basal insulin dose reduction when liraglutide is added, particularly in patients already near glycemic targets, to reduce hypoglycemia risk [14]. This recommendation emerged from post-market FAERS analysis of hypoglycemia reports in combination-therapy users [23].

Liraglutide Generic Status and Biosimilar Pathway

Liraglutide is a peptide drug regulated as a biologic under the Biologics Price Competition and Innovation Act. The 351(k) biosimilar approval pathway applies. As of mid-2025, no FDA-approved biosimilar of liraglutide (Victoza or Saxenda) has reached the US market, though several applications are in the FDA review pipeline [24].

What Biosimilar Approval Would Mean for the Label

An approved biosimilar liraglutide product would carry its own FDA-approved labeling, which may differ in minor respects from the reference product label. The biosimilar label must include the same Boxed Warning and core safety information as the reference product but may reflect updated post-market data not present in the original reference label [25]. Clinicians should check the specific prescribing information for any biosimilar product, not assume identical labeling.

Interchangeability Designation

The FDA's interchangeability designation (which would allow pharmacy-level substitution without prescriber intervention) requires additional switching-study data beyond the standard biosimilar pathway [25]. No liraglutide biosimilar has received an interchangeability designation as of July 2025.

Comparing Liraglutide Label Updates to Semaglutide: Clinical Context

Semaglutide (Ozempic, Wegovy, Rybelsus) is the GLP-1 receptor agonist most directly compared with liraglutide in clinical practice. Understanding how the two labels differ helps prescribers make evidence-based choices.

The STEP-1 trial (N=1,961, 68 weeks) showed semaglutide 2.4 mg produced 14.9% mean weight loss vs. 2.4% with placebo [26]. Liraglutide 3.0 mg in SCALE Obesity produced 8.4 kg absolute weight loss (approximately 8% of body weight) over 56 weeks [10]. The Saxenda label does not claim superiority to semaglutide, and head-to-head data from STEP-8 (N=338) confirmed semaglutide 2.4 mg produced significantly greater weight loss than liraglutide 3.0 mg (15.8% vs. 6.4% at 68 weeks) [27].

Prescribers should document in the medical record why liraglutide is chosen over semaglutide for weight management, particularly in patients with commercial insurance, as payers increasingly require prior authorization with step-therapy documentation.